Editorial: Biomarkers of Immune-Checkpoint-Inhibitor Immunotherapies in Hepatocellular Carcinomas.

Combination therapies targeting two immune checkpoint regulators (PD-1 and CTLA-4) or PD-1 concurrently with the angiogenic pathway prolong the overall survival time to nearly twice that of patients receiving monotherapy ([3]; also reviewed by He et al. below). Keywords: Hepatocellular carcinomas; biomarkers; immune-checkpoint inhibitors; PD-1; PD-L1; immunotherapies; bioinformatics EN Hepatocellular carcinomas biomarkers immune-checkpoint inhibitors PD-1 PD-L1 immunotherapies bioinformatics 1 2 2 03/14/22 20220310 NES 220310 Hepatocellular carcinomas (HCCs), made up of 75-85% of primary liver cancers, remain the leading cause of new cancer cases (>0.7 million) and cancer deaths (>0.6 million) globally according to the data collected up to 2020 before the coronavirus disease 2019 (COVID-19) pandemic ([1]). Hepatocellular carcinomas, biomarkers, immune-checkpoint inhibitors, PD-1, PD-L1, immunotherapies, bioinformatics. [Extracted from the article]